StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
CCEL$3.55+0.00%
Fair $3.55+0.0%

CCEL

Cryo-Cell International, Inc.

Healthcare / Medical Care FacilitiesNYSE American

$3.55

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $3.55Fund rank 26/100 · Data gapFallback financials|
SA 32/D
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 25%

FCF escenarios

weak_data · normalized FCF $2.4M · quality 44.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

32/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 16Warnings: 0unknown: 16
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · CCELLocal privado en este navegador · Cryo-Cell International, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$29M

P/E

N/A

•

EV/EBITDA

36.3x

↑

ROE

13.1%

↑

Gross Margin

76.6%

↑

Debt/Equity

-0.62

↓
52-Week Range$4
$3$6

TradingView lightweight chart

CCEL price, volumen y niveles de valoración

Último $3.550Periodo -52.7%
Fair value: $3.550

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2010–2025 · 15 años de histórico normalizado

Revenue CAGR

+3.9%

FCF CAGR

+6.9%

FCF margin

16.6%

FCF / Net income

-2.16x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $31.6M · net income $-2.4M · FCF $5.2M

2010-FY → 2025-FY

Gross margin

76.6%— pts

Operating margin

15.3%-3.5% pts

Net margin

-7.7%-27.2% pts

FCF margin

16.6%+5.7% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Income Statement
Revenue$31.6M$31.6M$32.0M$31.3M$30.3M————$25.4M$23.1M$21.1M$20.1M$19.0M$18.0M$17.9M$17.8M
Net Income$-2.4M$-2.4M$402095.00$-9.5M$2.8M$2.1M$3.6M$2.3M$-854824.00$2.3M$-1.3M$8.1M$553623.00$27436.00$-6.3M$-2.1M$3.5M
EBITDA$1.1M$1.1M$5.7M$-10.4M$6.7M$5.1M$8.0M$5.5M$5.5M$5.1M$588267.00$3.0M$2.2M$1.9M$-1.5M$84492.00$3.6M
EPS-0.30-0.300.05-1.150.330.250.450.27-0.110.30-0.160.830.050.00-0.56-0.180.29
Gross Margin76.6%76.6%75.2%73.2%71.0%————————————
Operating Margin15.3%15.3%11.8%11.1%14.7%————19.7%1.9%13.9%9.8%9.0%-9.5%-1.5%18.8%
Net Margin-7.7%-7.7%1.3%-30.4%9.1%————9.1%-5.7%38.4%2.8%0.1%-35.1%-11.7%19.5%
Balance Sheet
Debt/Equity-0.62-0.62-0.98-0.99-7.620.45-2.23-1.29-0.16-0.11-0.09-0.46-0.21-0.25-0.26-1.16-3.74
Current Ratio0.620.62———————————————
Cash Flow
Free Cash Flow$5.2M$5.2M$2.4M$1.3M$-8.6M$6.1M$8.4M$5.6M$4.9M$5.6M———$472196.00$227363.00$313407.00$1.9M
Returns
ROE13.1%13.1%-3.0%86.3%-181.8%49.8%-136.0%-32.9%9.6%-18.5%8.6%-163.3%-5.2%-0.3%70.1%85.2%-345.8%
Valuation
P/E——176.00—13.30————————————
EV/EBITDA36.3536.3514.87—7.09————————————
Growth & Yield
Revenue Growth-1.3%-1.3%2.0%3.3%—————9.8%9.7%4.8%6.0%5.7%0.3%0.9%—
EPS Growth-700.0%-700.0%104.4%-448.2%—-44.4%66.7%345.5%-136.7%287.5%-119.3%1560.0%—100.0%-211.1%-162.1%—
Dividend Yield17.2%17.2%———————————————

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -11.4%

Total return

-11.4%

Start / end P/E

n/dx → n/dx

EPS bridge

0.05 → -0.30

Residual

-28.6%

EPS growthn/d
Multiple reratingn/d
Dividend+17.2%
Residual / FX / buybacks / cross-term-28.6%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.